These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 21542674

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S, Buchner D, Craver C, Gayle J.
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E, Astara G, Madeddu C, Dessì M, Loi C, Lepori S, Mantovani G.
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [Abstract] [Full Text] [Related]

  • 7. Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study.
    Lin SJ, Hatoum HT, Buchner D, Cox D, Balu S.
    BMC Health Serv Res; 2012 Jul 23; 12():215. PubMed ID: 22823909
    [Abstract] [Full Text] [Related]

  • 8. Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.
    Hatoum HT, Lin SJ, Buchner D, Cox D.
    Support Care Cancer; 2012 May 23; 20(5):941-9. PubMed ID: 21533811
    [Abstract] [Full Text] [Related]

  • 9. The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.
    Schwartzberg LS, Jacobs P, Matsouka P, Azevedo W, Pinto A.
    Crit Rev Oncol Hematol; 2012 Jul 23; 83(1):59-70. PubMed ID: 22321726
    [Abstract] [Full Text] [Related]

  • 10. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM.
    J Support Oncol; 2003 Jul 23; 1(2):89-103. PubMed ID: 15352652
    [Abstract] [Full Text] [Related]

  • 11. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
    Yeh YC, McDonnell A, Klinger E, Fowler B, Matta L, Voit D, Reddy P.
    J Oncol Pharm Pract; 2011 Sep 23; 17(3):179-85. PubMed ID: 20452991
    [Abstract] [Full Text] [Related]

  • 12. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM.
    Expert Opin Drug Metab Toxicol; 2009 Dec 23; 5(12):1577-86. PubMed ID: 19929251
    [Abstract] [Full Text] [Related]

  • 13. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.
    Lancet Oncol; 2009 Feb 23; 10(2):115-24. PubMed ID: 19135415
    [Abstract] [Full Text] [Related]

  • 14. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB.
    Clin Adv Hematol Oncol; 2004 May 23; 2(5):284-9. PubMed ID: 16163194
    [Abstract] [Full Text] [Related]

  • 15. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group.
    Cancer; 2003 Dec 01; 98(11):2473-82. PubMed ID: 14635083
    [Abstract] [Full Text] [Related]

  • 16. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.
    Celio L, Denaro A, Agustoni F, Bajetta E.
    J Support Oncol; 2012 Dec 01; 10(2):65-71. PubMed ID: 22005217
    [Abstract] [Full Text] [Related]

  • 17. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
    Navari RM.
    Future Oncol; 2006 Oct 01; 2(5):591-602. PubMed ID: 17026451
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Igarashi K, Inatani H, Shimozaki S, Kato T, Aoki Y, Higuchi T, Tsuchiya H.
    Cancer Med; 2015 Mar 01; 4(3):333-41. PubMed ID: 25533447
    [Abstract] [Full Text] [Related]

  • 19. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients.
    Aapro MS, Macciocchi A, Gridelli C.
    J Support Oncol; 2005 Mar 01; 3(5):369-74. PubMed ID: 16218261
    [Abstract] [Full Text] [Related]

  • 20. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.
    J Support Oncol; 2006 Oct 01; 4(9):467-71. PubMed ID: 17080735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.